Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.

Authors: Nadine Houede, Thierry Chevallier, Jaffrelot Loic, Constance Thibault, Neuzillet Yann, Christine Abraham Jaillon, Alexandra Masson-Lecomte, Gwenaelle Gravis, Sophie Tartas, Damien Pouessel, Brigitte Laguerre, Francois Audenet, Evanguelos Xylinas, Luquiens Guillaume, Morgan Roupret

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.661

Source: Full article

---

Abstract

661